Pantorok Injection (Pantoprazole Sodium Sesquihydrate)

Adult dosage

When oral administration of pantoprazole is not appropriate, dissolve 1 vial of this drug (equivalent to 40 mg of pantoprazole) in 10 mL of saline for injection and administer by direct intravenous injection, or mix this solution with 100 mL of saline for injection or 5 % dextrose solution and administer intravenously over 2∼15 minutes. Discontinue intravenous pantoprazole and switch to oral pantoprazole 40 mg as soon as oral administration becomes possible. 1. Duodenal ulcer, gastric ulcer, moderate to severe reflux esophagitis Administer 1 vial of this drug (equivalent to 40 mg of pantoprazole) intravenously once daily. 2. Zollinger-Ellison syndrome and other pathological hypersecretory conditions - Start with an initial dose of 80 mg per day, then increase or decrease the dose according to measured gastric acid secretion. - Doses of 80 mg or more per day should be divided into 2 doses. - The dose may be temporarily increased to 160 mg or more, but only to the extent necessary to achieve adequate acid control. - When rapid acid control is required, an initial dose of 2 × 80 mg reduces acid output to the target range (< 10 mEq/h) within one hour in most patients. ◯ In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg of pantoprazole. ◯ In older adults or patients with renal impairment, the daily dose should not exceed 40 mg of pantoprazole.

This medication should not be administered to certain patients. It should not be used in patients with a history of allergy or hypersensitivity to this drug or any of its components, or to benzimidazole derivatives. It should also not be combined with certain medications being taken by the patient, such as atazanavir, nelpivirine, and rilpivirine. When using this medication, various adverse reactions may occur. Gastrointestinal symptoms may include abdominal pain, diarrhea, constipation, dyspepsia, and inflammation or thrombophlebitis at the injection site. Rarely, hepatic impairment or severe skin reactions, and severe allergic reactions such as anaphylaxis shock may occur, so caution is advised. Long-term use of this drug necessitates regular liver function tests and blood tests, and if liver function worsens, the medication should be discontinued. Also, long-term use for more than one year may increase the risk of fractures, hence caution is required. This drug reduces gastric acid secretion, thereby slightly increasing the risk of certain bacterial infections, particularly the risk of Clostridium difficile infection in hospitalized patients. Dizziness or visual disturbances may occur, so caution is needed during driving or machinery operation. This drug is metabolized by specific enzymes in the liver and may interact with other medications. In particular, caution should be taken when combined with methotrexate, atazanavir, nelpivirine, or rilpivirine as efficacy may decrease or toxicity may increase. It is advisable not to use this drug during the first three months of pregnancy; if necessary during pregnancy, it should be administered under a doctor's discretion considering the risks and benefits. Breastfeeding women are advised not to take this medication. Safety and efficacy in children and adolescents under 18 have not been sufficiently established, so it is recommended not to use it. In the event of overdose, there is no specific antidote, so appropriate treatment should be provided according to symptoms. This drug must be dissolved in an appropriate solvent before administration, and the prepared solution should be used within 12 hours. Before using, check for discoloration or cloudiness, and as it is for single use, unused medication should not be reused. Long-term use of this drug may increase the risk of gastric polyps such as fundic gland polyps, hence the minimum effective dose and shortest duration of use are recommended. Lastly, if symptoms similar to autoimmune diseases such as skin rash, fever, or arthralgia occur during the course of taking this medication, consult a physician immediately.

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, upper abdominal pain, diarrhea, constipation, abdominal distension, dyspepsia, gastric polyp, nausea, vomiting, dry mouth, rhinitis, injection site reactions, thrombophlebitis at the injection site, fever, peripheral edema, hyperthermia, elevated bilirubin, liver failure, jaundice, hepatocellular injury, elevated liver enzymes, arthralgia, myalgia, rhabdomyolysis, bone fracture, headache, dizziness, visual disturbances, taste disturbances, insomnia, sleep disorders, depression, hallucinations, disorientation, confusion, interstitial nephritis, pruritus, skin rash, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, photosensitivity reactions, gynecomastia, hyperlipidemia, increased lipids, weight changes, hyponatremia, hypomagnesemia, elevated CK, systemic lupus erythematosus, cutaneous lupus erythematosus, Clostridium difficile-associated diarrhea, paresthesia, DRESS syndrome, microscopic colitis, acute generalized pustular psoriasis, confusion, decreased mobility, speech disturbances, increased salivation, vertigo, tinnitus

This medication is sensitive to light and should be stored in a light-resistant container. It must also be stored in a sealed container to prevent air contact, and it is important to maintain the storage temperature below 25 degrees Celsius in a cool place.

Appearance

This medication is an injection with a white to almost white dry powder contained in a colorless, transparent vial.

Package unit

(40mg/vial) pack